1. Molecular mechanism underlying orofacial antinociceptive activity of Vanillosmopsis arborea Baker (Asteraceae) essential oil complexed with β-cyclodextrin
- Author
-
Renan G. Brito, Irwin Rose Alencar de Menezes, Laura Hévila Inocêncio Leite, Francisco Ernani Alves Magalhães, Bruno Anderson Fernandes da Silva, Adriana Rolim Campos, Paula dos Passos Menezes, Adriano Antunes de Souza Araújo, Henrique Douglas Melo Coutinho, José Galberto Martins da Costa, Lucindo José Quintans-Júnior, Sacha Aubrey Alves Rodrigues Santos, Gerlânia de Oliveira Leite, Mairim Russo Serafini, Claudener S. Teixeira, and Priscila L. Santos
- Subjects
Male ,Nociception ,Orofacial pain ,Analgesic ,Pharmaceutical Science ,Rodentia ,Asteraceae ,Pharmacology ,law.invention ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Facial Pain ,Oral administration ,law ,Drug Discovery ,Oils, Volatile ,medicine ,Animals ,Essential oil ,030304 developmental biology ,Analgesics ,0303 health sciences ,Plant Stems ,Plant Extracts ,Chemistry ,beta-Cyclodextrins ,Glutamate receptor ,Hypertonic saline ,Monocyclic Sesquiterpenes ,Complementary and alternative medicine ,Capsaicin ,030220 oncology & carcinogenesis ,Molecular Medicine ,medicine.symptom ,Sesquiterpenes - Abstract
Background Vanillosmopsis arborea Baker has recognized economic value owing to the high content of (-)-α-bisabolol (BISA) in the essential oil of its stem (EOVA). The antinociceptive effect of EVOA has already been demonstrated, and β-cyclodextrin (βCD) is known to improve the analgesic effect of various substances. Purpose Thus, we aimed to evaluate the orofacial antinociceptive effect of a complex containing EOVA-βCD in rodents. Methods EOVA was obtained by simple hydrodistillation, and the essential oil was complexed with βCD. The animals (n = 6/group) were treated orally with EOVA-βCD (10 or 50 mg/kg), or vehicle (control), and subjected to cutaneous orofacial nociception (formalin, capsaicin, acidic saline or glutamate), corneal (hypertonic saline) or temporomandibular (formalin) tests. The expression of FOS protein was analyzed in the spinal cord. Molecular docking was performed using the 5-HT3 and M2 receptors and BISA. Results The oral administration of EOVA-βCD reduced nociceptive behaviour. Moreover, EOVA-βCD decreased FOS expression. The molecular docking study indicates that BISA interacts with 5-HT3 and M2 receptors, indicating the potential mechanism of action of the tested compound. Conclusions Our results indicate that EOVA-βCD possesses orofacial antinociceptive effect, indicating that this complex can be used in analgesic drug development.
- Published
- 2019